Prevention of breast cancer by newer SERMs in the future

Recent Results in Cancer Research

Volumn 188, Issue , 2011, Pages 141-145

  Powles, Trevor ^a  

^a Parkside Oncology Clinic   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ARZOXIFENE; CHOLESTEROL; ESTROGEN RECEPTOR; LASOFOXIFENE; PLACEBO; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN;

ARTICLE; BONE DENSITY; BREAST CANCER; CANCER RISK; CHOLESTEROL BLOOD LEVEL; CHRONIC OBSTRUCTIVE LUNG DISEASE; CORONARY ARTERY DISEASE; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; ENDOMETRIAL DISEASE; ENDOMETRIUM CANCER; ENDOMETRIUM POLYP; ESTROGEN ACTIVITY; FRAGILITY FRACTURE; GALLBLADDER DISEASE; GYNECOLOGIC DISEASE; HIGH RISK POPULATION; HOT FLUSH; HUMAN; LEG CRAMP; LUNG INFECTION; MUSCLE CRAMP; OSTEOLYSIS; OSTEOPOROSIS; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; RISK REDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; STROKE; UTERUS DISEASE; UTERUS HYPERTROPHY; UTERUS MYOMA; VENOUS THROMBOEMBOLISM; VERTEBRA FRACTURE;

BREAST NEOPLASMS; FEMALE; HUMANS; PIPERIDINES; PYRROLIDINES; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TETRAHYDRONAPHTHALENES; THIOPHENES;

EID: 79551506171     PISSN: 00800015     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-642-10858-7_12     Document Type: Article

References (18)

1. Baselga J, Llombart-Cussac A et al (2003) Randomized, double-blind, multicenter trial comparing two doses of arzoxifene (LY353381) in hormone-sensitive advanced or metastatic breast cancer patients. Ann Oncol 14:1383-1390
2. Buzdar A, O'Shaughnessy J et al (2003) Phase II randomized, double-blind study of two dose levels of arzoxifene in patients with locally advanced or metastatic breast cancer. J Clin Oncol 21(6):1007-1014
3. Cummings S, Norton L et al (1998) Raloxifene reduces the risk of breast cancer and may decrease the risk of endometrial cancer in postmenopausal women. Two-year findings from the multiple outcomes of raloxifene evaluation (MORE) trial. Proc Am Soc Clin Oncol 17:2a.
4. Cummings S, Ensrud K et al (2010) Lasofoxifene in postmenopausal women with osteoporosis. N Engl J Med 362(8):686-696
5. Cuzick J, Forbes J et al (2002) First results from the International Breast Cancer Intervention Study (IBIS-I): A randomised prevention trial. Lancet 360:817-824
6. Cuzick J, Forbes J et al (2007) Long-term results of tamoxifen prophylaxis for breast cancer - 96 month follow-up of the randomised IBIS-I study. J Natl Cancer Inst 99:272-282
7. Deshmane V, Krishnamurthy S et al (2007) Phase III double-blind trial of arzoxifene compared with tamoxifen for locally advanced or metastatic breast cancer. J Clin Oncol 25(31):4967-4973
8. Fabian C, Kimler B et al (2004) Breast cancer chemoprevention phase I evaluation of biomarker modulation by arzoxifene, a third generation selective estrogen receptor modulator. Clin Cancer Res 10:5403-5417
9. Fisher B, Costantino J et al (1998) Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. JNCI 90(18):1371-1388 (Pubitemid 28439961)
10. Ke H, Foley G et al (2004) Long-term treatment of lasofoxifene preserves bone mass and bone strength and does not adversely affect the uterus in ovariectomized rats. Endocrinology 145(4): 1996-2005
11. LaCroix A, Powles T et al (2010) "Breast cancer incidence in the PEARL trial of lasofoxifene in postmenopausal osteoporotic women." JNCI (in press).
12. McClung M, Siris E et al (2006) Prevention of bone loss in postmenopausal women treated with lasofoxifene compared with raloxifene. Menopause 13(3):325-327
13. Powles TJ, Ashley S et al (2007) "Twenty-Year follow-up of the royal marsden randomized double- blinded tamoxifen breast cancer prevention trial. J Natl Cancer Inst 99(4):283-290
14. Powles T, Diem S et al (2009) Effects of arzoxifene on breast cancer incidence in postmenopausal women with osteoporosis or with low bone mass (Abstract). San Antonio Breast Cancer Symposium, Texas, USA.
15. Sato M, Turner C et al (1998) LY353381: a novel raloxifene analogue with improved SERM potency in vivo. Pharmacol Exp Ther 287:1-7
16. Shahana A, Thomas G et al (2009) Newly discovered breast cancer susceptibility loci on 3p24 and 17q23.2. Nat Genet 41:585-590
17. Suh N, Glasebrook A et al (2001) Arzoxifene, a new selective estrogen receptor modulator for chemoprevention of experimental breast cancer. Cancer Res 61(23):8412-8415
18. Vogel V, Costantino J et al (2006) Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes - the NSABP study of tamoxifen and raloxifene (STAR) P-2 trial. JAMA 295: 2727-2741